FDA Consultant Service Fees vs. FDA User Fees

Selling FDA-regulated products in the United States can require facility registration, establishment registration, product listing, premarket submissions, annual updates, biennial renewals, U.S. Agent designation, prior notice, labeling review, importer verification, adverse-event procedures, quality-system documentation, and other compliance work. The exact requirements depend on the product category, the company’s role, the manufacturing process, the claims made on the label, and whether the business is domestic or foreign.

The word “FDA fee” is frequently used as a catch-all expression. In practice, however, a company may face at least two fundamentally different charges. The first is a consultant service fee. This is the price charged by a private professional or company for performing regulatory work. The second is an FDA user fee. This is a statutory or government program fee collected in connection with certain registrations, applications, submissions, facility types, or regulatory programs.

FDA user fees are authorized under federal law and support defined regulatory programs. Depending on the program, a user fee may fund application review, scientific evaluation, inspections, performance improvements, information technology, program management, or other regulatory activities. User fees do not replace every part of FDA’s congressional funding, but they provide substantial program resources in areas such as medical devices, prescription drugs, generic drugs, biosimilars, animal drugs, and over-the-counter monograph drugs.

User fee amounts are generally tied to a federal fiscal year. The U.S. federal fiscal year begins October 1 and ends September 30. Rates can change each year, and the applicable rate is usually the rate in effect for the relevant fiscal year or submission date. This is why a company should not rely on an old article, invoice, screenshot, or prior-year quote when budgeting.

Some FDA-regulated sectors have no general registration user fee. Others have substantial annual fees or application fees. A business must therefore identify the exact regulatory program before calculating its government cost.

Medical device companies face one of the clearest examples of the difference between a consultant fee and a user fee. A consultant may charge to determine the establishment’s role, identify device classifications and product codes, prepare registration and listing information, coordinate U.S. Agent designation, help identify the initial importer, review labeling, and advise on premarket requirements. Separately, the FDA may require an annual establishment registration fee and a submission fee.

For fiscal year 2026, FDA lists an annual medical device establishment registration fee of $11,423. FDA also lists a standard 510(k) fee of $26,067 and a qualifying small-business fee of $6,517. Other submission types, including De Novo requests and PMAs, carry different and often much higher fees. Small-business reductions are not automatic; a company must qualify through the applicable FDA small-business determination process.

A device company should also understand that paying the establishment registration fee does not mean the device is cleared or approved. Registration and listing identify the establishment and devices in FDA systems. Premarket authorization is a separate legal question. Some Class I devices are exempt from 510(k), while other devices require 510(k), De Novo, PMA, or another pathway. The consultant’s job may include helping the company determine which pathway applies, but the consultant cannot convert an exempt device into an authorized device merely by completing registration.

Pharmaceutical fee structures can be considerably more complex than basic food or cosmetic registration. Prescription drug, generic drug, biosimilar, and other programs may impose application fees, program fees, facility fees, drug master file fees, supplement fees, or other charges. Domestic and foreign facilities may be assessed differently under certain programs.

Under the Generic Drug User Fee Amendments, FDA’s fiscal year 2026 schedule includes an ANDA fee of $358,247 and a Type II active pharmaceutical ingredient Drug Master File fee of $102,584. Facility fees include $43,549 for a domestic API facility, $58,549 for a foreign API facility, $238,943 for a domestic finished dosage form facility, and $253,943 for a foreign finished dosage form facility. Contract manufacturing organization rates also differ between domestic and foreign facilities.

These figures illustrate why a foreign drug manufacturer should obtain a written regulatory roadmap before making a U.S. market commitment. A low consultant registration fee does not eliminate six-figure government obligations when an application or facility falls under a user fee program. Conversely, not every company that sells a health-related product owes a pharmaceutical user fee. The product’s legal category and the company’s activities must be evaluated carefully.

Many FDA user fee programs apply to both domestic and foreign companies. A foreign medical device establishment, for example, does not avoid the annual establishment registration fee because it is located outside the United States. In some drug programs, foreign facility fees are higher than domestic facility fees. Foreign companies also face additional practical requirements, such as U.S. Agent designation, importer coordination, time-zone communication, translated documents, and cross-border payment arrangements.

A domestic company usually does not need a U.S. Agent for its own domestic establishment. A foreign food, drug, device, or cosmetic facility may need a U.S. Agent under the applicable program. The U.S. Agent’s role is not necessarily included in the government fee. It is a private representation service, and the scope should be stated clearly in the consultant agreement.

FDA user fees should be paid only through official payment channels identified by FDA. Companies should create the appropriate user fee account or cover sheet, follow the payment instructions for the specific program, and retain proof of payment. The payment reference must match the application, facility, or submission to which the fee applies. Sending money without the correct reference can delay processing.

Since October 1, 2025, FDA has stated that paper-based payments are no longer accepted for certain user fee processes, and payments must be made electronically in U.S. currency drawn on a U.S. bank through approved methods such as electronic check, credit card, or wire transfer, as applicable to the program. Payment procedures should be verified directly on the relevant FDA page because methods and limits may change.

Consultant service fees may be paid through the provider’s available methods, such as credit card, bank transfer, online invoice, or another agreed method. The consultant should issue an invoice or receipt identifying the service. The company should keep the consultant invoice separate from official FDA payment evidence.